Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Part D rebates could drive drug industry from US, PhRMA leader warns

This article was originally published in Scrip

Executive Summary

If Republican leaders in Congress seal a deal with their Democratic colleagues and the White House to apply mandatory Medicaid-style rebates to the Medicare Part D prescription drug programme as part of the ongoing debt ceiling negotiations, the biopharmaceutical industry may decide to pack its bags and say 'zai jian,' 'auf wiedersehen' or even 'hasta la vista, baby' to the US, the head of the pharmaceutical industry's lobbying group warned on 11 July.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts